Trials / Sponsors / Suzhou Transcenta Therapeutics Co., Ltd.
Suzhou Transcenta Therapeutics Co., Ltd.
Industry · 8 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metast Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer | Phase 3 | 2026-06-30 |
| Active Not Recruiting | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma | Phase 1 / Phase 2 | 2023-02-08 |
| Terminated | Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm | Phase 1 | 2021-06-11 |
| Recruiting | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or M Advanced Cancer | Phase 1 / Phase 2 | 2020-08-13 |
| Active Not Recruiting | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | 2020-05-28 |
| Terminated | A Study of MSB0254 Injection in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2020-04-01 |
| Completed | A Study of MSB2311 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2018-08-13 |
| Completed | A Phase I Study of MSB2311 in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2018-04-12 |